Clinical Case Reports (Jan 2022)

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel

  • Reyes Maria Martín‐Rojas,
  • Ignacio Gómez‐Centurión,
  • Rebeca Bailén,
  • Mariana Bastos,
  • Francisco Diaz‐Crespo,
  • Diego Carbonell,
  • Rafael Correa‐Rocha,
  • Marjorie Pion,
  • Cristina Muñoz,
  • Milagros Sancho,
  • Isabel Gómez Fernández,
  • Gillen Oarbeascoa,
  • Ana Pérez‐Corral,
  • Carolina Martínez‐Laperche,
  • Javier Anguita,
  • Ismael Buño,
  • Javier Menárguez,
  • Jose Luis Díez‐Martín,
  • Mi Kwon

DOI
https://doi.org/10.1002/ccr3.5209
Journal volume & issue
Vol. 10, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Chimeric antigen receptor (CAR) T cell–related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with poor prognosis and a challenging diagnosis. The establishment of specific diagnosis criteria is essential, and the combination of several techniques for CAR T‐cell follow‐up, allows a more precise management of this complication.

Keywords